Your browser doesn't support javascript.
loading
Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance.
Kuwana, Masataka; Sugiyama, Naonobu; Momohara, Shigeki; Atsumi, Tatsuya; Takei, Syuji; Tamura, Naoto; Harigai, Masayoshi; Fujii, Takao; Matsuno, Hiroaki; Takeuchi, Tsutomu; Yamamoto, Kazuhiko; Takasaki, Yoshinari; Tanigawa, Miki; Endo, Yutaka; Hirose, Tomohiro; Morishima, Yosuke; Yoshii, Noritoshi; Mimori, Tsuneyo; Takagi, Michiaki.
Afiliação
  • Kuwana M; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
  • Sugiyama N; Inflammation and Immunology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
  • Momohara S; Kusanagi Orthopedic Rheumatology Clinic, Shizuoka, Japan.
  • Atsumi T; Department of Orthopaedic Surgery, School of Medicine, Keio University, Tokyo, Japan.
  • Takei S; Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Tamura N; Pediatric Rheumatology, Medical Center for Children, Kagoshima University Hospital, Kagoshima, Japan.
  • Harigai M; Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
  • Fujii T; Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
  • Matsuno H; Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan.
  • Takeuchi T; Matsuno Clinic for Rheumatic Diseases, Toyama, Japan.
  • Yamamoto K; Department of Rheumatology, Keio University School of Medicine, Tokyo, Japan.
  • Takasaki Y; Saitama Medical University, Saitama, Japan.
  • Tanigawa M; The University of Tokyo, Tokyo, Japan.
  • Endo Y; Juntendo Koshigaya Hospital, Juntendo University Faculty of Medicine, Saitama, Japan.
  • Hirose T; Pfizer R&D Japan G.K., Tokyo, Japan.
  • Morishima Y; Pfizer R&D Japan G.K., Tokyo, Japan.
  • Yoshii N; Inflammation and Immunology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
  • Mimori T; Inflammation and Immunology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
  • Takagi M; Inflammation and Immunology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
Mod Rheumatol ; 34(2): 272-286, 2024 Feb 26.
Article em En | MEDLINE | ID: mdl-37405710
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Artrite Reumatoide / Pirimidinas / Antirreumáticos Tipo de estudo: Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans / Male País/Região como assunto: Asia Idioma: En Revista: Mod Rheumatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Artrite Reumatoide / Pirimidinas / Antirreumáticos Tipo de estudo: Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans / Male País/Região como assunto: Asia Idioma: En Revista: Mod Rheumatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão